Skip to main content

Table 4 Adverse events experienced during trastuzumab treatment in patients with HER2-positive breast cancer

From: Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study

System organ class n (%)
MedDRA preferred term
Any system organ class
Total 83 (23.9%)
Investigations 24 (6.9%)
Ejection fraction decreased 25 (7.2%)
Hepatic enzymes increased 1 (0.3%)
Blood and lymphatic system disorders 15 (4.3%)
Neutropenia 9 (2.6%)
Febrile neutropenia 8 (2.3%)
Lymphedema 1 (0.3%)
Gastrointestinal disorders 15 (4.3%)
Stomatitis 13 (3.7%)
Vomiting 10 (2.9%)
Abdominal pain upper 2 (0.6%)
Abdominal pain 1 (0.3%)
Dysphagia 1 (0.3%)
Gastritis 1 (0.3%)
Loose tooth 1 (0.3%)
General disorders and administration site conditions 14 (4.0%)
Pyrexia 9 (2.6%)
Pain 5 (1.4%)
Fatigue 1 (0.3%)
Cardiac disorders 16 (4.6%)
Cardiomyopathy 8 (2.3%)
Dyspnea 6 (1.7%)
Cardiac failure congestive 2 (0.6%)
Bradycardia 1 (0.3%)
Congestive cardiomyopathy 1 (0.3%)
Palpitations 1 (0.3%)
Nervous system disorders 9 (2.6%)
Neuropathy peripheral 6 (1.7%)
Dizziness 2 (0.6%)
Hypoesthesia 1 (0.3%)
Muscular weakness 1 (0.3%)
Musculoskeletal and connective tissue disorders 7 (2.0%)
Pain in extremity 5 (1.4%)
Arthralgia 2 (0.6%)
Back pain 1 (0.3%)
Bone pain 1 (0.3%)
Respiratory, thoracic and mediastinal disorders 6 (1.7%)
Cough 3 (0.9%)
Pleural effusion 1 (0.3%)
Pneumonitis 1 (0.3%)
Pulmonary embolism 1 (0.3%)
Infections and infestations 4 (1.1%)
Abscess limb 1 (0.3%)
Bronchitis 1 (0.3%)
Cellulitis 1 (0.3%)
Respiratory tract infection 1 (0.3%)
Injury, poisoning and procedural complications 4 (1.1%)
Cardiotoxicity 4 (1.1%)
Skin and subcutaneous tissue disorders 4 (1.1%)
Alopecia 1 (0.3%)
Dry skin 1 (0.3%)
Pigmentation disorder 1 (0.3%)
Pruritus 1 (0.3%)
Skin lesion 1 (0.3%)
Immune system disorders 3 (0.9%)
Hypersensitivity 2 (0.6%)
Skin reaction 1 (0.3%)
Renal and urinary disorders 3 (0.9%)
Flank pain 2 (0.6%)
Dysuria 1 (0.3%)
Urinary tract infection 1 (0.3%)
Reproductive system and breast disorders 2 (0.6%)
Endometrial hyperplasia 1 (0.3%)
Hematuria 1 (0.3%)
Ear and labyrinth disorders 1 (0.3%)
Otitis externa 1 (0.3%)
Metabolism and nutrition disorders 1 (0.3%)
Decreased appetite 1 (0.3%)
Vascular disorders 1 (0.3%)
Hot flush 1 (0.3%)
  1. Frequency of AEs is sorted in descending order in the total column
  2. A patient with multiple occurrences of an AE for a preferred term or system organ class is counted only once
  3. A patient with multiple AEs within a primary system organ class is counted only once in the total row